Logo
x

Search

Subscribe Now

UCB

UCB’s Bimzelx (Bimekizumab-bkzx) Secures the US FDA’s Approval for Treating Moderate to Severe Hidradenitis Suppurativa (HS)

UCB’s Bimzelx (Bimekizumab-bkzx) Secures the US FDA’s Approval for Treating Moderate to Severe Hidradenitis Suppurativa (HS)

  • November 21, 2024
UCB Reports the US FDA’s Acceptance of sBLA for Bimzelx (bimekizumab-bkzx) to Treat Hidradenitis Suppurativa

UCB Reports the US FDA’s Acceptance of sBLA for Bimzelx (bimekizumab-bkzx) to Treat Hidradenitis Suppurativa

  • April 5, 2024
UCB’s Bimzelx Receives CHMP’s Positive Opinion to Treat Moderate to Severe Hidradenitis Suppurativa

UCB’s Bimzelx Receives CHMP’s Positive Opinion to Treat Moderate to Severe Hidradenitis Suppurativa

  • March 22, 2024
UCB Receives the EC’s Approval for Rystiggo (rozanolixizumab) for the Treatment of Adults with Generalized Myasthenia Gravis (gMG)

UCB Receives the EC’s Approval for Rystiggo (rozanolixizumab) for the Treatment of Adults with Generalized Myasthenia Gravis (gMG)

  • January 8, 2024
UCB’s Zilbrysq (zilucoplan) Receives Approval from the EC to Treat Generalized Myasthenia Gravis (gMG)

UCB’s Zilbrysq (zilucoplan) Receives Approval from the EC to Treat Generalized Myasthenia Gravis (gMG)

  • December 4, 2023
UCB Reports the Results for Nayzilam in P-III Trial for the Treatment of Epilepsy

UCB Reports the Results for Nayzilam in P-III Trial for the Treatment of Epilepsy

  • November 1, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.